Sellas Life Sciences Group Inc (SLS) Stock Price, Quote & News

Company Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is adm...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 200 5278

Website: www.sellaslifesciences.com

Address:

7 Times Square, Suite 2503, New York, United States

Laacy Mar. 17 at 5:46 AM

$SLS $IBRX $SRPT $IOVA lets have a good day $CING needs a bad day so I can add.

0 · Reply

Mama710012 Mar. 17 at 5:26 AM

$SLS still

0 · Reply

HboFam Mar. 17 at 5:06 AM

$SLS A great find. @WangSLO “As expected, outcomes in patients who did not undergo HSCT in second remission were very poor, regardless of their response to salvage chemotherapy, with only 1 patient alive without relapse or death at 2 years.” 1 of 57 patients at 2 years. REGAL completed enrollment 2 years ago. This implies only 1 or 2 of the REGAL control arm patients have not died, or relapsed.

0 · Reply

posyche Mar. 17 at 5:06 AM

$SLS actually, enjoying the negativity on the board lately. good indication of fear of success. contrarian view at the moment, is that we are about to soar....calls added today, as stated earlier. did not make it to test 6.00 today as I expected, but still feel it will within a day or two... I believe we move before apr17, and actually shortly after earnings, mar19...and always, it's just an opinion....

0 · Reply

OnTheBalance Mar. 17 at 5:05 AM

$SLS If PFE shares are part of a take out deal payout, they would yield dividends of 6.46%, current price BMY shares, 4.65% dividends ABBV 3.45% MRK 2.95% As for future gainers stock price wise between these ... where can Sellas platforms make the biggest difference in the tightest timeframes?

1 · Reply

RealImbackbears Mar. 17 at 4:56 AM

$SLS $7.00 in Germany $4.00 in North Korea $10.00 in Greece

0 · Reply

IndependentGuidanceEdge Mar. 17 at 4:50 AM

$SLS is on the watchlist today, just monitoring calmly.

0 · Reply

RealImbackbears Mar. 17 at 4:38 AM

$SLS I think Maxim anyalst 10.00 PT istnt real. Scamgelos needs to buy shares on open market

0 · Reply

Rxpss6 Mar. 17 at 4:35 AM

$SLS per Dr. T pooled mOS = 30 months ~ that is correct based on exponential based PH but in reality pooled median is 15-17 months ~ implies regal is NPH, look at the below curve ; hazards collapsed after IA 3-4x. Off course it’s pooled hazards.

0 · Reply

RealImbackbears Mar. 17 at 4:33 AM

$SLS I got SDS Stergiou Derangement Syndrome Stergiou

1 · Reply

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

Mar 4, 2026, 12:59 PM EST - 12 days ago

What's Going With SELLAS Life Sciences Stock On Wednesday?

Jan 14, 2026, 8:30 AM EST - 2 months ago

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

Dec 29, 2025, 8:35 AM EST - 2 months ago

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

$SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025$

Dec 7, 2025, 6:00 PM EST - 3 months ago

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

Oct 29, 2025, 5:36 PM EDT - 4 months ago

SELLAS Life Sciences Group, Inc. (SLS) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs Transcript

Oct 27, 2025, 8:30 AM EDT - 5 months ago

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

Aug 19, 2025, 9:18 PM EDT - 7 months ago

Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026

Aug 7, 2025, 8:30 AM EDT - 7 months ago

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

Jul 7, 2025, 8:45 AM EDT - 9 months ago

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

Jun 5, 2025, 8:45 AM EDT - 10 months ago

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

Jun 2, 2025, 8:00 AM EDT - 10 months ago

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

May 20, 2025, 8:00 AM EDT - 10 months ago

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 15, 2025, 8:45 AM EDT - 10 months ago

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 13, 2025, 4:05 PM EDT - 10 months ago

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 8:45 AM EDT - 11 months ago

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

Apr 23, 2025, 10:23 AM EDT - 11 months ago

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2025, 8:45 AM EDT - 1 year ago

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

Mar 31, 2025, 3:03 PM EDT - 1 year ago

Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst

Mar 20, 2025, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 20, 2025, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

Jan 28, 2025, 3:11 PM EST - 1 year ago

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 23, 2025, 8:10 AM EST - 1 year ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Jan 8, 2025, 8:20 AM EST - 1 year ago

SELLAS Announces Key Business Objectives for 2025

Dec 10, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Dec 9, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

Nov 27, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

Nov 13, 2024, 4:15 PM EST - 1 year ago

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 8:00 AM EST - 1 year ago

voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)

Nov 5, 2024, 9:55 AM EST - 1 year ago

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

Oct 15, 2024, 8:45 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

Oct 10, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Aug 13, 2024, 4:10 PM EDT - 1 year ago

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 6, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Jul 16, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

Jul 8, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

Jun 24, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

Jun 17, 2024, 9:05 AM EDT - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

Jun 10, 2024, 8:40 AM EDT - 1 year ago

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

May 14, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 1, 2024, 8:35 AM EDT - 2 years ago

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

Apr 29, 2024, 8:45 AM EDT - 2 years ago

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

Apr 19, 2024, 1:49 PM EDT - 2 years ago

Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout

Mar 28, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 26, 2024, 7:35 AM EDT - 2 years ago

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

Mar 19, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 19, 2024, 8:47 AM EDT - 2 years ago

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

Mar 15, 2024, 9:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 8, 2024, 8:00 AM EST - 2 years ago

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

Mar 1, 2024, 8:30 AM EST - 2 years ago

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

Laacy Mar. 17 at 5:46 AM

$SLS $IBRX $SRPT $IOVA lets have a good day $CING needs a bad day so I can add.

0 · Reply

Mama710012 Mar. 17 at 5:26 AM

$SLS still

0 · Reply

HboFam Mar. 17 at 5:06 AM

0 · Reply

posyche Mar. 17 at 5:06 AM

0 · Reply

OnTheBalance Mar. 17 at 5:05 AM

1 · Reply

RealImbackbears Mar. 17 at 4:56 AM

$SLS $7.00 in Germany $4.00 in North Korea $10.00 in Greece

0 · Reply

IndependentGuidanceEdge Mar. 17 at 4:50 AM

$SLS is on the watchlist today, just monitoring calmly.

0 · Reply

RealImbackbears Mar. 17 at 4:38 AM

$SLS I think Maxim anyalst 10.00 PT istnt real. Scamgelos needs to buy shares on open market

0 · Reply

Rxpss6 Mar. 17 at 4:35 AM

0 · Reply

RealImbackbears Mar. 17 at 4:33 AM

$SLS I got SDS Stergiou Derangement Syndrome Stergiou

1 · Reply

kiwigram Mar. 17 at 4:27 AM

$SLS sentiment is back to bearish - thankfully we aren't trending anymore though

0 · Reply

SLSorDie Mar. 17 at 4:10 AM

$SLS When like now you witness a sudden huge surge in the number of fake bear accounts who insist on tagging SLS in every reply, know that the bear case is desperate, they are trying so hard to get anyone to sell SLS/ not buy more. And this for me is an even stronger sign that we longs are on the right track.

0 · Reply

Thestokinator Mar. 17 at 4:02 AM

$SLS well most of that 955 mil is pulled out of estimates including call issuing..... how much of that is actual baked short? We dont know but 49 million is real and who knows how much total likely 100 to 500 million. If HR is less than 0.3 we will have a game stop moment with share pri e reaching up to 330 plus within 7 day time before the covering exhausts and the price returns to earth. No betting on this but its a likely scenario.

2 · Reply

WangSLO Mar. 17 at 3:44 AM

$SLS old article from dec 10 2020. Let's try to keep the info recent and relevant

1 · Reply

FlockOfSeagulls Mar. 17 at 3:38 AM

$SLS Overall Survival (OS) data for MRD-negative AML patients in CR2 who are ineligible for transplant is limited, achieving MRD negativity significantly improves the prognosis compared to those who are MRD-positive. For these patients, the 5-year OS is estimated at approximately 34% to 37% with intensive therapy, though this is heavily influenced by their ability to maintain remission through further chemotherapy or targeted treatments. The pumper crew here is doing exactly what their name implies. They pump. https://pmc.ncbi.nlm.nih.gov/articles/PMC7757010/

1 · Reply

Darkhorse34 Mar. 17 at 3:31 AM

$SLS

0 · Reply

TheFrogPrince Mar. 17 at 3:24 AM

$SLS #patientmoneythemovie

0 · Reply

RealImbackbears Mar. 17 at 3:21 AM

$SLS I got Stergiou Derangement Syndrome

0 · Reply

RealImbackbears Mar. 17 at 3:19 AM

$SLS dod Stergiou just cash in more warrants ?

0 · Reply

amessagefromtheodd Mar. 17 at 3:15 AM

$SLS GPS has the right setup—low toxicity that keeps patients on therapy, clear immune activation through T-cell response, and early signs of durability—so meaningful curve separation and a sustained survival tail beyond a few years are plausible- regal patients have been alive for over 3 years : Considering the durability factors and low if any toxicity, we inference tail curve from gps, there is enough evidence that leans to that conclusion and its plausibility- for that matter gps separation can be that credible. On the other hand- Comparing AMPLIFY-7P to REGAL isn’t scientifically valid for a conclusions- it’s just not a reliable basis for conclusions because they’re different trials asking different questions under different conditions, so any apparent advantage you see across them is more narrative than evidence.

0 · Reply

wanderlust222 Mar. 17 at 3:03 AM

$SLS If the synthetic shorting is real we need to start planning for the future. This will become a movie and we need a good cast. As a subtle nod to Dumb Money, I think Paul Dano should be cast as Run4Roses aka 100X aka 67X. He's better in that kind of edgy, psychotic role. For John Montana, I think we should seriously consider Gary Busey. He might be a little difficult to work with, but I think he'll be great at capturing his essence.

2 · Reply

yG19 Mar. 17 at 2:59 AM

$SLS As I was putting together the SLS-009 due diligence in the past few weeks, I shared this in the DD, but this was a real golden nugget and explains why a cure fraction is occurring biologically in REGAL. The WT1 "Catch-22." The biggest failure mode in cancer immunotherapy is antigen escape: the cancer stops expressing the target and becomes invisible to the immune system. CD19-negative relapses occur in 10-30% of CAR-T patients. But WT1 is not a surface marker like CD19. It is a transcription factor inside the nucleus that drives leukemia stem cell self-renewal and survival. The NCI ranked WT1 #1 out of 75 cancer antigens for this reason. If a leukemia cell downregulates WT1 to hide from GPS-trained immune cells, it loses the transcriptional program keeping it alive -- self-renewal collapses, proliferation stops. The cancer faces a biological Catch-22: keep expressing WT1 and remain visible to the immune system, or drop WT1 and die. This is why there is a cure fraction happening.

1 · Reply

Market Cap	764.91M
Revenue (ttm)	0.00
Net Income (ttm)	-30.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,543,300
Avg Vol	8,401,542
Day's Range	N/A - N/A
Shares Out	142.44M
Stochastic %K	36%
Beta	2.18
Analysts	Strong Sell
Price Target	$6.83